Baili Tianheng announced that the company's first and only EGFR × HER3 dual antibody ADC, Rencan ilontuzumab/Yizekang, which was independently developed by the company and was approved for marketing, a phase III clinical trial of locally advanced or metastatic non-small cell lung cancer with EGFR-sensitive mutations that failed prior EGFR-TKI treatment was judged by an independent data monitoring committee, and the main end point of progression-free survival was also observed in the predetermined mid-term analysis. This is the fourth phase III clinical study where the dual antibody ADC reached the main end point. It is also the first phase III clinical study in the world where the dual antibody ADC drug reached the main end point in the treatment of non-small cell lung cancer. Currently, the drug has been approved for marketing by the State Drug Administration for 2 indications, and the marketing application for 1 indication has been accepted by the CDE.

Baili Tianheng announced that the company's first and only EGFR × HER3 dual antibody ADC, Rencan ilontuzumab/Yizekang, which was independently developed by the company and was approved for marketing, a phase III clinical trial of locally advanced or metastatic non-small cell lung cancer with EGFR-sensitive mutations that failed prior EGFR-TKI treatment was judged by an independent data monitoring committee, and the main end point of progression-free survival was also observed in the predetermined mid-term analysis. This is the fourth phase III clinical study where the dual antibody ADC reached the main end point. It is also the first phase III clinical study in the world where the dual antibody ADC drug reached the main end point in the treatment of non-small cell lung cancer. Currently, the drug has been approved for marketing by the State Drug Administration for 2 indications, and the marketing application for 1 indication has been accepted by the CDE.